Patent Ductus Arteriosus

A congenital heart defect characterized by the persistent opening of fetal DUCTUS ARTERIOSUS that connects the PULMONARY ARTERY to the descending aorta (AORTA, DESCENDING) allowing unoxygenated blood to bypass the lung and flow to the PLACENTA. Normally, the ductus is closed shortly after birth.

Also Known As:

Networked: 2309 relevant articles (100 outcomes, 192 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Hemorrhage
2.	Birth Weight (Birth Weights)
3.	Pulmonary Hypertension (Ayerza Syndrome)
4.	Pneumothorax
5.	Bronchopulmonary Dysplasia

Experts

1.	Clyman, Ronald I: 19 articles (06/2014 - 09/2003)
2.	Erdeve, Omer: 16 articles (01/2015 - 09/2008)
3.	McNamara, Patrick J: 15 articles (01/2015 - 07/2010)
4.	Dilmen, Ugur: 14 articles (07/2014 - 04/2009)
5.	Ohlsson, A: 12 articles (01/2008 - 01/2001)
6.	Uras, Nurdan: 10 articles (07/2014 - 04/2011)
7.	Sehgal, Arvind: 9 articles (05/2015 - 07/2010)
8.	Cheatham, John P: 8 articles (09/2015 - 10/2009)
9.	Ohlsson, Arne: 8 articles (01/2015 - 01/2010)
10.	Jain, Amish: 8 articles (09/2014 - 04/2012)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Patent Ductus Arteriosus:

1.	Indomethacin (Indometacin)FDA LinkGeneric 06/01/1988 - "Indomethacin has proven effective in closing the patent ductus arteriosus (PDA) in most low birth weight (LBW) neonates with this disorder. " 04/01/2013 - "After the introduction of a new protocol based on the early treatment with indomethacin for patent ductus arteriosus, the objective of this study was to assess the safety and efficacy of this new practice in comparison with the safety and efficacy of the conventional treatment in a high-risk population. " 04/01/2004 - "Is oral indomethacin effective in treatment of preterm infants with patent ductus arteriosus?" 11/01/1998 - "Postnatally, therapeutic indomethacin administration is usually effective in mediating patent ductus arteriosus (PDA) constriction in premature infants. " 09/01/1993 - "Indomethacin has been demonstrated to be effective for closure of hemodynamically symptomatic patent ductus arteriosus (PDA) in premature infants. "
2.	Ibuprofen (Motrin)FDA LinkGeneric 01/01/2013 - "There are few published reports concerning the efficacy of oral ibuprofen for the treatment of patent ductus arteriosus (PDA) in extremely low birth weight (ELBW) infants. " 05/01/2000 - "This study was aimed at evaluating the efficacy of ibuprofen in the prophylaxis of patent ductus arteriosus (PDA) in very preterm neonates and at detecting eventual side-effects. " 04/01/2012 - "Improved closure of patent ductus arteriosus with high doses of ibuprofen." 04/01/2012 - "Our aim was to assess the hypothesis that a high-dose regimen of ibuprofen is more effective than the standard-dose regimen in closing patent ductus arteriosus (PDA) without increasing adverse effects. " 11/01/2012 - "Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus."
3.	Acetaminophen (Paracetamol)FDA LinkGeneric 01/01/2016 - "To compare the efficacy of oral and intravenous paracetamol for closure of hemodynamically significant patent ductus arteriosus (HSPDA) in very low birth weight (VLBW) preterm infants. " 08/01/2015 - "In our experience, lower-dose paracetamol is effective in closing the patent ductus arteriosus in 83.3% of the cases." 08/01/2015 - "Intravenous paracetamol with a lower dose is also effective for the treatment of patent ductus arteriosus in pre-term infants." 11/01/2014 - "Paracetamol was reported to be effective for patent ductus arteriosus (PDA) closure. " 05/01/2015 - "[Paracetamol could be useful in the treatment of patent ductus arteriosus in the very-low-birth-weight infant]."
4.	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 08/01/2013 - "To evaluate safety and efficacy of closure of patent ductus arteriosus (PDA) with Amplatzer duct occluder II Additional Sizes (ADO II AS) and to report early and midterm results of the device in children and very young symptomatic infants. " 09/01/2005 - "The Amplatzer duct occluder (ADO) provides a safe and effective therapy for patients with moderate- to large-sized patent ductus arteriosus (PDA), but there have been few reports of transcatheter closure of very large PDAs in young children and infants. " 06/01/2012 - "The objective of this study was to evaluate the technical feasibility, safety, and efficacy of the new device Amplatzer duct occluder II additional sizes (ADO II AS) for closure of patent ductus arteriosus (PDA). " 01/01/2001 - "The aim of the study was to assess the safety and efficacy of the Amplatzer ductal occluder (ADO) in transcatheter occlusion of patent ductus arteriosus (PDA). " 07/15/2004 - "This study compared the efficacy and costs of the most used approaches for percutaneous closure of large patent ductus arteriosus, that is, multiple coils and the Amplatzer duct occluder (ADO) device. "
5.	Alprostadil (Muse)FDA LinkGeneric 02/01/1993 - "The study demonstrates the efficacy of PGE1 in maintaining the patency of the ductus arteriosus; we therefore propose that this drug should be used, though with caution, routinely in peripheral hospitals before such patients are transferred to specialised centres for further diagnostic and therapeutic intervention." 11/01/2013 - "In order to maintain patency of the ductus arteriosus (DA), the first line treatment is Prostaglandin E1 and the second step is the surgical creation of aortic-pulmonary shunt. " 03/01/1994 - "Prostaglandin E1 (PGE1) infusion, initiated to achieve patency of the ductus arteriosus, produced improved oxygenation and cardiovascular status in both infants. " 09/01/2014 - "Prostaglandin E1 was required to be maintained the patency of the ductus arteriosus (PDA) in 39 cases (Group I) while it was not administered in 22 cases (Group II). " 04/01/2013 - "Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation."
6.	Furosemide (Lasix)FDA LinkGeneric 01/01/2011 - "Furosemide-induced transient improvement in pulmonary function did not outweigh an increased risk for patent ductus arteriosus and for hemodynamic instability. " 01/01/2008 - "Furosemide-induced transient improvement in pulmonary function did not outweigh an increased risk for patent ductus arteriosus and for hemodynamic instability. " 01/01/2001 - "Furosemide-induced transient improvement in pulmonary function did not outweigh an increased risk for patent ductus arteriosus and for hemodynamic instability. " 01/01/2000 - "Furosemide-induced transient improvement in pulmonary function did not outweigh an increased risk for patent ductus arteriosus and for hemodynamic instability. " 02/01/2010 - "Furosemide increases prostaglandin production and may be associated with patent ductus arteriosus (PDA). "
7.	OxygenIBA 08/01/2014 - "This study aimed to examine the differences between arterial and inferior caval vein oxygen saturation, fractional oxygen extraction, and the shunt index, which were calculated in the diagnosis of patent ductus arteriosus. " 07/01/2015 - "Immature antioxidant and oxygen-sensing mechanisms are involved in the pathogenesis of the patent ductus arteriosus (PDA). " 09/01/2014 - "To investigate IVC oxygen saturation during the first three days of life in preterm infants with and without patent ductus arteriosus (PDA). " 09/01/2014 - "Inferior Vena Cava Oxygen Saturation during the First Three Postnatal Days in Preterm Newborns with and without Patent Ductus Arteriosus." 08/01/2014 - "The early measured differences between arterial and inferior caval vein oxygen saturation and inferior body fractional oxygen extraction were found to be lower and the shunt index was found to be higher in the haemodynamically significant patent ductus arteriosus group than in the group without haemodynamically significant patent ductus arteriosus. "
8.	SteroidsIBA 01/01/2012 - "The rate of patent ductus arteriosus was increased in the group receiving inhaled steroids [RR 1.64 (95% CI 1.23 to 2.17); RD 0.21 (95% CI 0.10 to 0.33); one trial, n = 278; NNTH 5 (95% CI 3 to 10)]. " 01/01/2003 - "There was a statistically significant increase in the rate of patent ductus arteriosus (RR 1.64, 95% CI 1.23, 2.17; RD 0.21, 95% CI 0.10, 0.33; 1 trial and n = 278) in the group receiving inhaled steroids. " 08/01/2012 - "As compared with BS, FS was more likely to be associated with lower birthweight, vaginal delivery, patent ductus arteriosus, postnatal steroids, multiple central lines, longer respiratory support and hospital stay, and higher mortality (P < 0.05). " 07/01/2007 - "When intermediate risk factors for BPD were also added to the model, the effect of steroids disappeared; ventilation (OR = 3.03), increased illness severity (OR = 1.11), and patent ductus arteriosus (OR = 1.90) were significant risk factors. " 07/01/1998 - "Birthweight, gestational age, race, day of first extubation, antenatal or postnatal steroids, patent ductus arteriosus status and maximal mean airway pressure used were of no value in predicting success or failure at 72 hours, 1, or 2 weeks. "
9.	nitinolIBA 02/01/2014 - "This study assessed the feasibility and efficacy of implanting a new miniaturized nitinol device to occlude the patent ductus arteriosus (PDA) in a newborn porcine model. " 12/01/2014 - "The Nit-Occlud PDA is a nitinol coil-type patent ductus arteriosus (PDA) occluder with a reverse cone configuration, which is implanted using a controlled delivery system. " 01/01/2014 - "Patients' defects were closed with various types of occluders made of nitinol wire mesh occluder, patent ductus arteriosus (PDA) type. " 01/01/2013 - "Transcatheter patent ductus arteriosus closure with the pan-nitinol occluder can be performed safely and successfully in a canine model and shows good biological compatibility and low mortality rates." 01/01/2013 - "Pan-nitinol occluder and special delivery device for closure of patent ductus arteriosus: a canine-model feasibility study."
10.	ROPIBA 01/01/2010 - "Patent ductus arteriosus was more common among infants with ROP. " 08/01/2004 - "Severe ROP was associated with the presence of a patent ductus arteriosus (PDA) (OR: 3.31; 95% CI: 1.11-9.90) and birth in time period 3 versus time periods 1 and 2 combined (OR: 6.28; 95% CI: 2.10-18.74). " 01/01/2014 - "There were significant benefits for the following outcomes: lower rates of failure to extubate and decreased risks of chronic lung disease at both 28 days and 36 weeks' postmenstrual age, death or chronic lung disease at 28 days and 36 weeks' postmenstrual age, patent ductus arteriosus and ROP, including severe ROP. " 01/01/2011 - "To evaluate whether the presence of patent ductus arteriosus (PDA) increases the rate of retinopathy of prematurity (ROP) or its severity. " 06/01/2009 - "There were no significant differences in the proportion of patients with respiratory distress syndrome, patent ductus arteriosus, severe intraventricular hemorrhage, ROP or CLD between the two groups. "

Therapies and Procedures

1.	Ligation 11/01/2003 - "Video-assisted thoracic surgery is a safe and effective technique for patent ductus arteriosus ligation in premature infants, including those with very low and extremely low birth weight." 06/01/1996 - "Open surgical ligation has proven to be a safe and effective method to bring about closure of the patent ductus arteriosus (PDA). " 06/01/1984 - "Results indicate that surgical ligation is a safe and effective procedure for treating patent ductus arteriosus with large left-to-right shunting in small premature infants." 12/01/1996 - "Cost and efficacy of surgical ligation versus transcatheter coil occlusion of patent ductus arteriosus." 04/01/1995 - "These data support the premise that children older than 3 months undergoing elective ligation of a patent ductus arteriosus have been treated with improved efficiency and less charge without an increase in postdischarge morbidity. "
2.	Catheters 04/01/2010 - "In conclusion, catheter closure using the Amplatzer duct occluder II is an effective and safe therapy for most patients with patent ductus arteriosus. " 11/15/1988 - "Catheter occlusion of the patent ductus arteriosus using the Rashkind umbrella appears to be a safe and effective method of non-surgical management." 08/01/2010 - "Document safety and efficacy of transvenous catheter occlusion of patent ductus arteriosus (PDA) over a wide range of ductal and patient sizes. " 07/01/1983 - "A single film portable aortogram through a highly placed umbilical artery catheter suggested aortic atresia, but subsequent study revealed a normal aorta and a patent ductus arteriosus. " 09/01/2014 - "We report a novel technique 'the kissing catheter technique' for retrieval of a broken catheter fragment in a patient undergoing closure of a patent ductus arteriosus. "
3.	Septal Occluder Device 02/01/2007 - "This technique may represent a clinically effective and less expensive alternative to the use of an Amplatzer duct occluder (Amplatzer Medical UK) in dogs with medium-sized patent ductus arteriosus. " 08/01/2009 - "In children under 1 year of age, percutaneous closure of patent ductus arteriosus using an Amplatzer occluder was a safe and effective procedure. " 08/01/2009 - "In children under 1 year of age, percutaneous closure of patent ductus arteriosus using an Amplatzer occluder was a safe and effective procedure. " 03/01/2015 - "Closure of large patent ductus arteriosus using the Amplatzer Septal Occluder." 06/01/2013 - "To evaluate short term results of percutaneous patent ductus arteriosus (PDA) closure in a cohort of pediatric and adult patients following closure with the Amplatzer Ductal Occluder (ADO-1 and ADO-2) and Amplatzer Septal Occluder (ASO) devices. "
4.	Artificial Respiration (Mechanical Ventilation) 01/01/2014 - "The risk of BPD was lower in AC than in non-AC multiples (aOR 0.41, CI 0.20-0.87), and this finding did not change after controlling for mechanical ventilation (aOR 0.42, CI 0.20-0.85) or presence of a patent ductus arteriosus (aOR 0.39, CI 0.18-0.84). " 04/01/2013 - "A persistent left-to-right shunt through a patent ductus arteriosus (PDA) increases the rate of hydrostatic fluid filtration into the lung's interstitium, impairs pulmonary mechanics, and prolongs the need for mechanical ventilation. " 12/01/2011 - "Patent ductus arteriosus, mechanical ventilation and uteroplacental insufficiency were significantly associated with delayed passage. " 01/01/2010 - "In AGA infants mean gestation was significantly shorter (p < 0.001), and IRDS grade III/IV (p = 0.015), mechanical ventilation (p = 0.045) and patent ductus arteriosus (p = 0.003) were significantly more prevalent. " 03/01/2007 - "Independent predictors of duration of mechanical ventilation were: gestational age <28 weeks, degree of respiratory distress syndrome (RDS) at birth, significant patent ductus arteriosus (PDA), the SNAP-score, and high levels of CXCL8 (>4,153 pg/ml) in TA only in neonates with a gestational age <28 weeks. "
5.	Thoracotomy 01/01/2014 - "We reported the data of 127 small children's who underwent standard transaxillary thoracotomy (101 patients - Group I) and video-assisted thoracoscopic surgery for patent ductus arteriosus clipping (26 patients - Group II). " 01/01/2014 - "Thoracoscopic clipping of the patent ductus arteriosus is an alternative to conventional surgical closure via thoracotomy in low birth weight infants. " 07/01/2013 - "Closure of a patent ductus arteriosus in pre-term neonates using a left anterior mini-thoracotomy." 04/01/2011 - "Comparison of posterolateral thoracotomy and video-assisted thoracoscopic clipping for the treatment of patent ductus arteriosus in neonates and infants." 01/01/2010 - "A left thoracotomy was performed, the coil was removed and the patent ductus arteriosus was ligated."